Compare BioNTech SE - ADR (BNTX) vs Wheaton Precious Metals Corp (WPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Wheaton Precious Metals Corp — how do they compare? BioNTech SE - ADR trades at $90.88 (market cap $22.86B), while Wheaton Precious Metals Corp trades at $108.65 (market cap $48.84B). The key difference: Wheaton Precious Metals Corp is far larger — about 2.1× BioNTech SE - ADR's market cap, and Wheaton Precious Metals Corp pays a 0.72% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | WPM | |
|---|---|---|
Market Cap | $22.86B | $48.84B |
Sector | Health | Basic Materials |
52-Week High | $119.34 | $165.72 |
52-Week Low | $83.89 | $88.32 |
Enterprise Value | $6.53B | $46.68B |
Dividend Yield | — | 0.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
Wheaton Precious Metals (WPM) trades at $107.83, down 2.02% today, showing bearish technical signals with strong resistance at $108-$110. Fundamentally, the company demonstrates robust performance with Q1 2026 EPS beating expectations at $1.28 versus $1.24, continuing a trend of earnings surprises. Revenue grew to $2.31 billion in 2025 with impressive 65.55% net income margin, though valuation ratios remain elevated with P/E at 27.25.
The stock presents a compelling opportunity with 80% analyst buy ratings and $161.75 consensus price target, representing 50% upside potential. Key risks include precious metal price volatility and the bearish technical outlook. Record cash flow generation and strong production growth support the positive fundamental story despite near-term price pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Wheaton Precious Metals Corp
Wheaton Precious Metals Corp is a precious metal streaming company. The company has entered into over 20 long-term purchase agreements with 17 different mining companies, for the purchase of precious metals and cobalt. It has streaming agreements covering approximately 19 operating mines and 9 development stage projects. The company's projects include Vale's Salobo mine and silver streams on Glencore's Antamina mine and Goldcorp's Penasquito mine.
Read more on WPM →
